NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
Rhea-AI Summary
NewcelX (Nasdaq: NCEL) submitted a Pre-IND briefing package to the FDA for NCEL-101, a stem cell-derived islet therapy for type 1 diabetes, in combination with Eledon’s tegoprubart.
A Type B pre-IND meeting is scheduled for late June to review manufacturing, preclinical plans and First-In-Human trial design.
Positive
- Pre-IND package submitted to FDA for NCEL-101 First-In-Human trial
- NCEL-101 targets type 1 diabetes using stem cell-derived islet cells
- Planned combination with tegoprubart, an anti-CD40L monoclonal antibody
- Type B pre-IND FDA meeting scheduled for last week of June
- Tegoprubart experience in more than 100 transplant recipients cited
- Tegoprubart-based regimen supported by 12-patient islet transplant study data
Negative
- None.
News Market Reaction – NCEL
In the May 27 session, NCEL gained 9.52%, reflecting a notable positive market reaction. Argus tracked a peak move of +19.6% during that session. Argus tracked a trough of -7.9% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Earnings & funding | Positive | +28.9% | 2025 results plus NCEL-101 acceleration and new financing access highlighted to investors. |
| Apr 20 | Program spotlight | Positive | +6.4% | Corporate presentation update emphasizing NCEL-101 and strategic tegoprubart collaboration. |
| Apr 01 | Equity financing | Positive | +10.8% | Premium-priced private placement and warrants to help fund NCEL-101 development. |
| Mar 09 | Strategic collaboration | Positive | -1.1% | Collaboration with Eledon to combine NCEL-101 with anti-CD40L antibody tegoprubart. |
| Feb 12 | Publication & CVR | Positive | +1.1% | Peer-reviewed data supporting Mazindol IR/SR and progress on CVR monetization strategy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent NCEL news has generally seen positive price alignment, with four of the last five announcements producing gains, including strong moves on financing and NCEL-101 development updates, and one divergence on a collaboration announcement.
Over the past few months, NewcelX has repeatedly highlighted NCEL-101 as its flagship Type 1 Diabetes program and deepened collaboration with Eledon Pharmaceuticals. In March–April 2026, the company announced the strategic collaboration, a premium-priced $1.35M private placement, and updated corporate materials around the combined NCEL-101/tegoprubart strategy, all generally followed by positive price moves. Today’s Pre-IND submission and scheduled FDA Type B meeting build directly on those steps toward a First-In-Human trial.
Key Terms
pre-investigational new drug regulatory
pre-ind regulatory
first-in-human medical
monoclonal antibody medical
calcineurin inhibitor-free medical
immunosuppressive regimen medical
anti-cd40l medical
type b pre-ind meeting regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial
ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug (“Pre-IND”) briefing package to the U.S. Food and Drug Administration (“FDA”) to support the proposed First-In-Human (“FIH”) clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (“Eledon”; Nasdaq: ELDN). The submission represents a significant milestone toward the clinical development of an innovative treatment intended for a potential cure for type 1 diabetes.
NewcelX is seeking to advance NCEL-101, an enriched stem cell-derived islet product candidate, into clinical studies with Eledon’s investigational anti-CD40L monoclonal antibody, tegoprubart, serving as the cornerstone of a calcineurin inhibitor-free immunosuppressive regimen. The combination is designed to enable durable graft survival and function, with the goals of achieving outcomes comparable to donor human islet transplantation and advancing a potential functional cure for type 1 diabetes. This approach is supported by recently reported results from a 12-patient investigator-initiated study at University of Chicago Medicine in patients with type 1 diabetes, where tegoprubart-based immunosuppression preserved transplanted islet function and maintained durable immune protection (Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine).
Tegoprubart has been used as an investigational immunosuppressive agent in more than 100 transplant recipients across studies conducted under multiple FDA-cleared Investigational New Drug applications. This body of clinical transplant experience provides important safety, dosing, and immunologic insights that are directly relevant to islet cell replacement therapies and support the planned advancement of NCEL-101.
A Type B pre-IND meeting has been scheduled with the FDA for the last week of June. NewcelX plans to discuss NCEL-101 manufacturing, the preclinical (safety/toxicology study) development plan and FIH clinical trial design.
Ronen Twito, Executive Chairman & CEO of NewcelX, added, “The Pre-IND meeting for NCEL-101 is a pivotal milestone that underscores our commitment towards a potential cure for T1D. We are encouraged both by our continued interactions with the FDA and by the FDA’s recent commitment to streamlining the IND process for T1D innovations.”
About NewcelX
NewcelX is an innovative biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes. Built on a validated human pluripotent stem cell (hPSC) platform, the company’s lead program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. NewcelX is advancing a comprehensive therapeutic approach for Type 1 Diabetes integrating cell therapy, immune protection, and translational science to address critical unmet medical needs.
Social Media: LinkedIn, Facebook, X, Instagram
Website: www.newcelx.com
Forward-Looking Statements
This press release contains expressed or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. For example, NewcelX is using forward-looking statements when it discusses clinical development of an innovative treatment intended for a potential cure for type 1 diabetes, advancing NCEL-101 into clinical studies with Eledon’s investigational anti-CD40L monoclonal antibody, the planned advancement of NCEL-101, the Company’s expectations concerning its pre-IND interactions with the U.S. Food and Drug Administration (the “FDA”), the timing, scope and outcome of any FDA feedback, the potential initiation, timing, design and progress of future preclinical studies or clinical trials, the advancement of the Company’s development programs and the regulatory pathway for its product candidate. These forward-looking statements and their implications are based on the current expectations of the management of NewcelX and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the regulatory pathways that NewcelX may elect to utilize in seeking European Medicines Agency, the FDA, and other regulatory approvals; its ability to drive revenue growth, enhance research and development capabilities, and improve financial performance is subject to uncertainties; that its financial position raises substantial doubt about its ability to continue as a going concern; its ability to maintain listing and effectively comply with the listing requirements of the Nasdaq; changes in technology and market requirements; potential delays or obstacles in launching or completing clinical trials, including its expectations regarding the timing of commencing further clinical trials, the process entailed in conducting each such trial, including dosages, and the order of such trials with each of its product candidates or whether such trials will be conducted at all; competitive companies, technologies and its industry; the development and commercialization, if any, of any other product candidates that it may seek to develop; products that may not be approved by regulatory agencies; technologies that may not be validated or accepted by the scientific community; the inability to retain or attract key employees; unforeseen scientific difficulties with products in development; the scope of protection it is able to establish and maintain for intellectual property rights covering its product candidates and its ability to operate its business without infringing the intellectual property rights of others; higher-than-expected product costs; results in the laboratory that do not translate to clinical success; insufficient patent protection; possible adverse safety outcomes; its ability to establish and maintain strategic partnerships and other corporate collaborations; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; delays in developing or introducing new technologies, products, or applications; competitive pressures that could reduce market share or pricing; the overall global political and economic environment in the countries in which we operate; and security, political and economic instability in the Middle East that could harm its business, including due to the current security situation in Israel. Except as otherwise required by law, NewcelX does not undertake any obligation to publicly release revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission ("SEC") and available at www.sec.gov, as well as in subsequent filings made by NewcelX.
Investor Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
NewCelX@kcsa.com
Company Contact
Sarah Bazak
InvestorRelations@newcelx.com
